| 000 | 01757 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513232924.0 | ||
| 264 | 0 | _c20010419 | |
| 008 | 200104s 0 0 eng d | ||
| 022 | _a0007-0920 | ||
| 024 | 7 |
_a10.1054/bjoc.2000.1637 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDoz, F | |
| 245 | 0 | 0 |
_aPhase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cMar 2001 |
||
| 300 |
_a604-10 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aDrug Hypersensitivity _xetiology |
| 650 | 0 | 4 |
_aEthanol _xpharmacokinetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 |
_aNeoplasm, Residual _xdrug therapy |
| 650 | 0 | 4 |
_aNeurotoxicity Syndromes _xetiology |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xpharmacokinetics |
| 650 | 0 | 4 |
_aSolvents _xpharmacokinetics |
| 700 | 1 | _aGentet, J C | |
| 700 | 1 | _aPein, F | |
| 700 | 1 | _aFrappaz, D | |
| 700 | 1 | _aChastagner, P | |
| 700 | 1 | _aMoretti, S | |
| 700 | 1 | _aVassal, G | |
| 700 | 1 | _aArditti, J | |
| 700 | 1 | _aTellingen, O V | |
| 700 | 1 | _aIliadis, A | |
| 700 | 1 | _aCatalin, J | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 84 _gno. 5 _gp. 604-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1054/bjoc.2000.1637 _zAvailable from publisher's website |
| 999 |
_c11174718 _d11174718 |
||